Breast cancer is the leading cause of cancer-related death in women worldwide. Expression of the WWOX tumor suppressor is absent or reduced in a large proportion of breast tumors suggesting that loss of WWOX may contribute to breast tumorigenesis. Wwox-deficient mice die by 3-4 weeks of age precluding adult tumor analysis. To evaluate the effect of WWOX-altered expression on mammary tumor formation, the Wwox-heterozygous allele was back crossed onto the C3H mammary tumor-susceptible genetic background (Wwox C3H þ /À) and incidence of mammary tumor formation was evaluated. Although 50% of the female Wwox C3H þ /À mice developed mammary carcinomas, only 7% of Wwox C3H þ / þ mice did. Intriguingly, mammary tumors in Wwox C3H þ /À mice frequently lost WWOX protein expression suggesting a genetic predisposition toward mammary tumorigenesis. Immunohistochemical staining of hormone receptors revealed loss of estrogen receptor-a (ER) and progesterone receptor in the majority of these tumors. In vitro, depletion of WWOX in MCF7 ER-positive cells led to reduced ER expression and reduced sensitivity to tamoxifen and estrogen treatment and was associated with enhanced survival and anchorageindependent growth. Finally, cDNA array analyses of murine normal mammary epithelial cells and mammary tumors identified 163 significantly downreguated and 129 upregulated genes in the tumors. The majority of differentially expressed genes were part of pathways involved in cellular movement, cell-to-cell signaling and interaction, cellular development, cellular growth and proliferation and cell death. These changes in gene expression of mouse mammary tumors in Wwox C3H þ /À mice resemble, at least in part, human breast cancer development. Our findings demonstrate the critical role that the WWOX tumor suppressor gene has in preventing tumorigenesis in breast cancer.
Introduction
Breast cancer is still one of the most common types of tumors, affecting one woman out of eight, and is the second leading cause of cancer death in women in the USA (Jemal et al., 2010) . The model of breast cancer progression suggests that its development involves defined pathological and clinical stages, starting with ductal hyperproliferation, with subsequent evolution into in situ and invasive carcinomas, and finally into metastatic disease (Polyak, 2007) . Genome-wide microarray and copy number analyses revealed that breast tumors exhibit a diverse pattern of genetic changes when compared with normal mammary gland epithelial cells (Perou et al., 2000) . Although enormous advances have been made in understanding breast cancer, the etiology and molecular signaling pathways that contribute to breast cancer formation remain largely elusive.
The WWOX gene encoding a protein with tumor suppressor function, a WW domain-containing oxidoreductase (Del Mare et al., 2009) , was originally identified as a putative tumor suppressor in breast cancer as it lies in a fragile genomic region (FRA16D) that is frequently altered in pre-neoplastic and neoplastic lesions (Bednarek et al., 2000; Ried et al., 2000) . Indeed, expression of WWOX is deregulated in twothirds of breast cancer cases (Guler et al., 2005; Nunez et al., 2005) . We and others have recently reported that WWOX loss is a frequent event in breast cancers that are negative for estrogen receptor (ER), progesterone receptor (PR) and HER2 (triple negative (Sorlie et al., 2001) ) and that loss of WWOX expression is associated with nodal metastasis and unfavorable outcome (Aqeilan et al., 2007a; Guler et al., 2009) ). Loss of heterozygosity and hypermethylation affecting WWOX have been reported as main causes of WWOX alterations in breast tumors (Bednarek et al., 2000; Iliopoulos et al., 2007) . Furthermore, ectopic expression of WWOX in WWOX-negative breast cancer cells suppresses tumorigenicity (Iliopoulos et al., 2007) . These findings suggest that alteration of WWOX expression may have roles in the pathogenesis of breast cancer.
Recently, we generated a mouse carrying a targeted deletion of the Wwox gene (Aqeilan et al., 2007c) . Spontaneous osteosarcomas were observed in juvenile Wwox-null mice before their death, whereas targeted loss of one allele increased the incidence of spontaneous and chemically induced lung and forestomach tumors (Aqeilan et al., 2007b, c; Kurek et al., 2010) thus confirming Wwox bona fide tumor suppressor function. At the biochemical level, cumulative evidence suggests that WWOX has an indispensable role in several signaling pathways , however, the molecular mechanism of WWOX tumor suppressor function remains largely unknown.
In this study, we set out to determine whether targeted ablation of Wwox in mice is associated with mammary tumor formation. To this end, we partially transferred the Wwox þ /À allele into the C3H mammary tumor-susceptible genetic background mice and monitored mammary tumor development. We found that Wwox þ /À mice are significantly more prone to spontaneous mammary tumor formation as compared with wild-type (Wwox þ / þ ) control littermates and that these tumors closely resemble human breast cancers. Our findings provide the first in vivo evidence that WWOX has critical roles in the pathogenesis of breast cancer.
Results and discussion
Mammary tumor incidence in C3H-Wwox mice We previously reported that Wwox þ /À mice on B6-129 mixed background develop higher incidence of lung tumors as compared with Wwox þ / þ mice (Aqeilan et al., 2007c) . We also noted that some of these mice develop mammary tumors though with very low penetrance (data not shown). These data prompted us to examine the effect of WWOX altered expression on mammary tumor formation using the C3H mammary tumor-susceptible genetic background. The Wwoxheterozygous allele was back crossed onto the C3H background for three rounds (N3/F1; B87% purity) and mammary tumor burden compared with wild-type littermate animals was assessed. Monitoring of mice for 18-months revealed that Wwox C3H þ /À developed mammary tumors earlier and at a higher frequency than Wwox C3H þ / þ mice did. In particular, 50% (9/18) of Wwox C3H þ /À mice developed mammary tumors compared with 7% (1/14) of Wwox C3H þ / þ mice ( Table 1 ). The number of tumor-bearing animals among Wwox C3H þ /À mice was 7-fold higher (P ¼ 0.019) than that of wild-type mice (Table 1 ). The incidence of tumors per mouse in Wwox C3H þ /À mice was 11-fold higher than . This C3H/HeJ mouse strain purchased from Jackson Laboratory does not carry the mouse mammary tumor virus and females are known to develop spontaneous mammary tumors by age of 6-15 months (http://tumor. informatics.jax.org/mtbwi/tumorFrequencyGrid.do;jsessionid ¼ D9E7769C40B059F342610671F2B3C2B8). To evaluate spontaneous mammary tumors, 32 of N3-C3H female mice (8-18 months of matched age) were killed and autopsies were performed after CO 2 asphyxiation. Tissues were fixed in 10% phosphate-buffered formalin and examined histologically by two pathologists after hematoxylin and eosin staining for the presence of hyperplasia, DCIS and carcinomas. Tumor incidence was analyzed by two-tailed Fisher's test and tumor multiplicity using one-way analysis of variance. P-values o0.05 were considered statistically significant. Italic indicates normal tissues.
in Wwox C3H þ / þ mice (Po0.001). The median age of Wwox C3H þ /À mice that developed mammary tumors was 13 months whereas the only wild-type animal that developed tumors was 18 months old. These data suggest that additional genetic alterations that accumulate with time might be required for tumor development. Of note, only a small percentage of wild-type N3/F1-C3H mice develop mammary tumors, perhaps, due to the mixed genetic background of the colony. That such statistical significance was achieved with a relatively small number of mice suggest that targeted deletion of Wwox in the C3H background is indeed associated with increased incidence of spontaneous mammary tumor formation, though larger cohort of pure mice would be necessary in the future to further validate these findings.
Mammary tumor phenotype in C3H-Wwox þ /À mice Although mammary carcinomas were rare in Wwox C3H þ / þ mice (1/14), they were the most prevalent tumor type in Wwox C3H þ /À mice, accounting for half of the mice (Table 1) . Mammary tumors originated in both the inguinal and thoracic glands with a latency of 8-18 months. All of the female heterozygous mice that developed mammary abnormalities developed ductal carcinoma in situ ( Figure 1A -b) and poorly differentiated invasive ductal carcinomas ( Figures 1A-c and d ). Three cases demonstrated squamous cell carcinomas, invasive ductal carcinoma with epidermoid metaplastic features ( Figure 1A -e). Two animals (M26 and M27) developed at least three separate primary mammary tumors in different glands that were of different histological types (Table 1) . Epithelial hyperplasia was detected in female Wwox C3H mice that did not develop mammary tumors including wild-type mice. Cumulatively, these data suggest that inactivation of Wwox in mice is associated with mammary tumor phenotypes resembling those developing in breast cancer (Guler et C3H þ /À female mice ( Â 20) as described previously (Kurek et al., 2010) . Polyclonal anti-WWOX antibody (Guler et al., 2009 ) at a dilution of 1:10 000 was used. Tumors were grouped into three categories (positive, reduced, negative) based on the intensity of cytoplasmic staining in all tumor cells present on the slides. The 'positive' category was assigned when the intensity was equivalent to that found in normal mammary glands from healthy tissues (f). The 'reduced' category was used for tumors with clearly diminished intensity (g, h) and 'negative' category for IDC tumors with no WWOX immunostaining as in i and j. Magnification bars represents 100 mm. (C) Expression of specific markers in mammary tissues from Wwox C3H þ /À female mice ( Â 60) was performed as described (Gao et al., 2005) in normal (upper) and tumors (lower). Magnification bars represent 20 mm. Antibodies used were: mouse monoclonal anti-ER-a antibody (ER: 6F11 1:25 from Novocastra Lab, Newcastle upon Tyne, UK), rabbit polyclonal anti-PR (PR: A0098 1:250 from Dakocytomation, Carpinteria, CA, USA) and cytokeratine 14 (CK14: LL002, 1:8000 from AbD-Serotec, Raleigh, NC, USA).
Frequent loss of WWOX, ER and PR in mammary tumors from Wwox
C3H þ /À mice To analyze the status of the WWOX protein expression in mammary tumors developed in Wwox C3H þ /À mice, we next performed immunohistochemical analyses using anti-WWOX antibody. WWOX expression was uniformly strong in the cytoplasm of the normal mammary epithelial glands ( Figure 1B-f) . The intensity of WWOX in ductal carcinoma in situ was attenuated as compared with normal glands (Figure 1B-g ). In 79% (11/14) of the mammary tumors, there was partial or complete loss of WWOX ( Figures 1B-h-j) . These results suggest that the second wild-type allele of WWOX might be lost in mammary tumors from Wwox C3H þ /À mice suggesting loss of heterozygosity and that inactivation of both WWOX alleles might accelerate mammary tumor formation. Further, our data in mice are consistent with reduced levels of WWOX in more advanced stages (G-III) of human breast tumors (Aqeilan et al., 2007a) .
To better characterize these tumors, we next evaluated the expression of ER and PR using immunohistochemical staining. We found that in most of the poorly differentiated tumors (grade III), expression of ER and PR was lost (Table 1, Figure 1C ). By contrast, ER and PR staining was retained in the well-differentiated (grade I) tumors, as in normal mammary glands (Table 1) . We have also examined the expression of cytokeratine 14, a basal cell marker, in these tumors and found that most tumors strongly expressed cytokeratine 14 ( Figure 1C) . In univariate analysis, WWOX loss was more frequent in ER and PR negative basal-like tumors (Table 2 ). These data suggest that characteristics of mammary tumors in Wwox C3H þ /À mice resemble those of human breast cancers where WWOX loss is associated with triple negative basal-like (CK5/6) breast cancers (Guler et al., 2009 ). This group, accounting for 15% of all breast cancers, is often characterized by BRCA1 mutations. Being a DNA repair protein, BRCA1 was previously shown to be important in loss of fragile genes, such as WWOX (Turner et al., 2002) . Therefore, it is likely that inactivation of the BRCA1 pathway in basal/triple negative-cancers may contribute to loss of WWOX expression in these cancers.
Depletion of WWOX in MCF7 cells is associated with enhanced survival and anchorage-independent growth The preceding observations suggest that WWOX loss might enhance mammary tumor cell growth. Therefore, we next investigated whether loss of WWOX expression in ER-positive MCF7 cells enhances its tumorigenic traits. To do so, we generated MCF7 cells containing a stably integrated WWOX-targeting small hairpin RNA expression vector. Immunoblot analysis confirmed that the expression of WWOX was reduced by more than 80% in two cell clones stably transfected with WWOX small hairpin RNA (MCF7shWWOX), compared with that of control small hairpin RNA-transfected cells (Figures 2a and b) . We next examined these cells for their in vitro cell growth behavior. Colony formation assay demonstrated that WWOX-depleted MCF7 cells grew more colonies as compared with control cells (Figure 2c ). Next, we examined whether knockdown of WWOX in MCF7 cells is associated with anchorageindependent cell growth. We found that reduced WWOX expression strongly enhanced growth in soft agar of MCF7 cells (Figure 2d ). These results suggest that depletion of WWOX in MCF7 cells is associated with a tumorigenic phenotype.
Knockdown of WWOX in MCF7 cells is associated with reduced ER expression and function
Our results also suggest that WWOX loss might deprive breast cancer cells of attributes, which when lost are associated with high-grade malignancy, that is, loss of ER expression ( Figure 1C ). To determine whether knockdown of WWOX in MCF7 resembles loss of WWOX in mammary tumors in Wwox C3H þ /À mice, we examined if WWOX-depleted MCF7 cells display loss of ER expression. We found that levels of ER were significantly downregulated in WWOX-depleted MCF7 cells compared with MCF7-EV cells as assessed by western blot and real-time PCR analyses (Figures 2a  and e) . To determine the functional relevance of this downregulation, we examined the effect of Tamoxifen (Tam) and 17b-estradiol (E 2 ) treatments on the different cell clones. Tam acts primarily through ER by modulation of gene expression leading to inhibition of proliferation of breast cancer cells (Radmacher and Simon, 2000) . To examine the sensitivity of WWOXdepleted MCF7 cells to Tam treatment and E 2 , cells were incubated in serum-free RPMI-1640 medium containing 10 À6 Tam or 10 À9 E 2 and cell proliferation was determined. We found that although Tam treatment attenuated control cell growth, WWOX-depleted MCF7 cells were significantly less sensitive (Figure 2f ). In the presence of E 2 , WWOX-depleted MCF7 cells showed reduced proliferation as compared with control MCF7 (Figure 2g ). The modest differences in response to either Tam or E 2 could be attributed to the fact that WWOX knockdown leads to downregulation and not to total depletion of ER. Nevertheless, our findings suggest that knockdown of WWOX levels in MCF7 ER-positive cells is associated with tumorigenic traits and that WWOX loss in breast cancer may affect ER signaling mRNAs profiling using Affymetrix analysis To further determine the molecular and cellular functions of tumor suppressor WWOX in mammary tumor development, we studied the differential expression of mRNAs in invasive ductal carcinomas tumors developed in Wwox C3H þ /À mice compared with control mammary epithelial cells. The mRNAs were analyzed using mouse ** *** Figure 2 Phenotypes of WWOX depletion in MCF7 cells. (a) Establishment of MCF7 stable clones depleted of WWOX using lentiviral vector carrying small hairpin RNA against WWOX sequence. As control, empty vector (EV) was used. Cells were lysed using 0.5% NP40, 50 mM Tris-HCL (pH7.5), 150 mM NaCl, 0.5 mM EDTA, 10% glycerol and 1 Â protease inhibitor (Calbiochem, Gibbstown, NJ, USA). Western blot analysis of WWOX expression (using goat polyclonal anti-WWOX antibody, 1:1000, sc-20529) in MCF7-shWWOX and -EV cells showing knockdown of 480% of WWOX expression in two clones is shown (CL1 and 3) (upper panel). Middle panel shows expression of ER protein in WWOX-depleted MCF7 cells using anti-ER (H184) antibody (sc-7207). GAPDH served as loading control. (b) WWOX mRNA relative expression in WWOX-depleted MCF7 cells as determined by real-time reverse transcriptase (RT-PCR) analysis. Total RNA was isolated from the different clones followed by homogenizing in TRI-reagent (Sigma, St Louis, MO, USA)) according to the manufacturer's protocol. The cDNA was synthesized with oligo(dT) primers using the Super-Script first strand synthesis kit (Applied Biosystems (ABI), Foster City, CA, USA) according to the manufacturer's protocol. Gene expression was assessed by quantitative real time PCR (ABI) using primers listed in Supplementary Table 3 . UBC cDNA served as internal control. Columns, mean of triplicate samples from two independent experiments; bars, s.d. (c) Effect of WWOX depletion on survival, as assessed by colony formation assay. MCF7 cells were plated at a density 5 Â 10 2 /well in a six-well plate in triplicate. After 10 days, cells were fixed with 70% ethanol, stained with Giemsa and colonies were counted. Columns, mean of triplicates samples; bars, s.e.m., (Po0.001). (d) Effect of WWOX depletion on anchorage-independent growth, as assessed by soft agar assay. Cells were plated between two layers of agarose. The agar base was prepared by melting agar 1% in water at 42 1C and mixed with an equal volume of RPMI 2 Â containing 20% fetal calf serum. The plates were kept at 4 1C for at least 30 min. The top layer was prepared by melting agarose 0.7% in water that was mixed with an equal volume of RPMI 2 Â and 5000 cells/well in triplicate. This solution was then gently poured on the base layer. The plates were incubated at 37 1C for 14-21 days. Colonies were detected by crystal violet staining and then counted. Columns, mean of triplicates samples; bars, s.e.m. (Po0.001). (e) ESR1 mRNA relative expression in WWOX-depleted MCF7 cells was determined by real-time RT-PCR analysis as in b. (f, g) Effect of Tamoxifen (f) and 17b-estradiol (g) treatment on MCF7shWWOX growth rate. MCF7 cells were grown for 2 days without E 2 and then incubated in serum-free medium containing ethanol (0.2%), 10 À6 Tam or 10 À9 E 2 . Proliferating cells were analyzed at the indicated time points using an XTT (sodium 3 0 -[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) proliferation assay according to the manufacturers instruction (Biological Industries, Beit Haemek, Israel). WWOX-depleted cells were less responsive to Tam and E2 treatment in the different clones. Relative living cells ratio represents the ratio between the optical density obtained from treated cells to that obtained from untreated cells. ** represents Po0.01 and *** represents Po0.001 as analyzed by two tailed Student's t-test.
Affymetrix microarray gene-chip 430 2.0 arrays (Affymetrix, Santa Clara, CA, USA). The analysis revealed numerous genes that exhibited modified expression levels in the mammary tumors (Supplementary Table 1 ). Principal component analysis of all samples revealed that this gene set effectively separates tumors from normal epithelial cells (Supplementary Figure 1) . To challenge the statistical significance of the microarray results, we performed volcano analysis, using a threshold of 4-fold in gene expression with cutoff P-value o0.001 ( Figure 3a) . We identified 163 significantly downregulated and 129 significantly upregulated genes in mammary tumors (Supplementary Table 2 ). Examples of upregulated transcripts in tumors include Sox4, Akt1, Scd2 and Timp2 whereas Cxcl1, Il6 and Has1 were downregulated. To validate some of the most significant observations, we performed quantitative reverse transcriptase PCR of various relevant transcripts. We confirmed the increase in expression of several genes in mouse mammary tumors, including Scd2, Timp2 and Trim2 (Figure 3b) . Similarly, a significant decrease in expression of several transcripts including Il-6, Timp4, Has1 and Wwox was confirmed in Wwox C3H þ /À mammary tumors (Figure 3c ). Although in some tumors we observed a mixed pattern, likely due to contamination with stromal cells, these data suggest that WWOX loss is associated with differential expression of tumorrelated genes.
Hierarchical unsupervised clustering of gene expression revealed the presence of 4 major clusters (Figure 3d ). Of these, two clusters included genes that were strongly upregulated or downregulated in tumors (tu) as compared with normal samples (no) (Figure 3d) . In order to better understand the biological function of these genes, we used the Ingenuity (IPA) system algorithms. We found multiple pathways that are altered in tumors including cellular movement, cell-to-cell signaling and interaction, cellular development, cellular growth and proliferation and cell death (Supplementary  Table 3 ). Interestingly, several differentially expressed genes identified in tumors of Wwox C3H þ /À mice are well documented in human breast cancers and in other Figure 3 Affymetrix analysis of mammary tumors from Wwox-heterozygous mice. Total RNAs were isolated from five mammary tumors from five Wwox C3H þ /À mice and three normal mammary epithelial glands from three control Wwox C3H þ /À littermate mice. RNAs were hybridized with Affymetrix mouse gene-chip 430 2.0 arrays. (a) Volcano plot analysis of the differentially expressed genes (log 2 scale) versus the P values of the genes (Àlog 10 scale). The quality assurance, calibration, data normalization, principal component analysis, and volcano plot for the Affymetrix cell format files were performed by Partek Genomics Suite 6.5 (Partek Genomics, St Louis, MO, USA). Genes with a fourfold expression difference and cutoff P-valueso0.001 were defined significant. The dots at the left upper side of the plot represent the statistically significant downregulated genes in tumors, whereas those at the right upper side represent the genes that were upregulated in tumors. (b, c) Real-time PCR validation of six deregulated genes in six mammary tumors and two normal mammary epithelial cells. Total RNA was isolated using Tri-reagent (Sigma). RNA (1 mg) was reversed transcribed using the iScript cDNA synthesis kit (Applied Biosystems). Real-time PCR was done using SYBR Green PCR Master Mix (Applied Biosystems). Ubc was used as control. Columns, mean of triplicates samples; bars, s.d. Supplementary Table 4 shows list of primer sequence used for real-time PCR. (d) Heat map of commonly deregulated genes in Wwox þ /À mammary tumors relative to normal mammary tissues. Negative fold change (transcripts with decreased expression in tumors) is represented in green and positive fold change (transcripts with increased expression in tumors) is represented in red.
mammary tumor mouse models (Hu et al., 2004; Klein et al., 2007) .
In conclusion, we propose that loss of WWOX expression in mouse mammary tissues is associated with significant genetic and molecular changes that in turn contribute to mammary tumor formation. These tumors were mostly ER/PR-negative, a feature characterizing aggressive tumors and those with worse outcome, resembling loss of WWOX in human breast cancers. Our findings may suggest that Wwox C3H þ /À mice might be used as a tool to study inactivation of WWOX in human breast cancer.
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